Pharmaceuticals

The pharmaceutical industry develops and commercialises medicines to prevent infection, maintain health and cure disease, and patents are a vital tool by which pharma companies protect and/or secure a return on their huge financial investments. At Beck Greener, we understand the challenges faced by pharma companies in developing and commercialising new products which enables us to provide commercially-focused advice and assistance in obtaining and protecting the rights of our clients and challenging the rights of third parties to preserve freedom to operate.

Overview

Meet the team

Jump to :

Beck Greener has an established track record of providing invaluable assistance to our pharma clients in both protecting their ideas and establishing their freedom to operate.

We have in depth experience with every aspect of pharmaceutical innovation from the drugs themselves, including both small and large molecules, peptides, proteins, monoclonal antibodies and vaccines, to formulations of the drugs and from drug delivery methodologies via the oral, rectal, topical, transdermal and parenteral routes for either local or systemic effect to both established and emerging production methods.

We are also well used to navigating the different examination laws and practices specific for pharmaceutical inventions in over 80 countries around the world, enabling us to establish truly global patent portfolios for our clients both efficiently and effectively.

Establishing portfolio for UK-based pharmaceutical start-up

We work closely with a specialist biotech company developing systems for the manufacture of bespoke medicines using innovative 3D printing technologies. The client develops not only new drug formulations having improved release profiles but also new 3D printers for producing the medicines, together with the software for controlling operation of the machines. We help the client identify and protect new inventions and advise on pathways to avoid infringing others’ rights.

Dr Catherine Jewell and Dr James Stones are recognised as thought leaders in the area of IP aspects of 3D printing of pharmaceuticals having written several publications on the subject including a chapter in the book entitled “3D printing of pharmaceuticals” (Basit et al, AAPS Press, 2018) and been invited to speak on this subject at conferences.